CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients

JCI Insight
Diane GoltzDimo Dietrich

Abstract

Recent years have witnessed the groundbreaking success of immune checkpoint blockage (ICB) in metastasized malignant melanoma. However, biomarkers predicting the response to ICB are still urgently needed. In the present study, we investigated CTLA4 promoter methylation (mCTLA4) in 470 malignant melanoma patients from The Cancer Genome Atlas (non-ICB cohort) and in 50 individuals with metastasized malignant melanomas under PD-1/CTLA-4-targeted immunotherapy (ICB cohort). mCTLA4 levels were quantified using the Infinium HumanMethylation450 BeadChip (non-ICB cohort) and methylation-specific quantitative real-time PCR in DNA formalin-fixed and paraffin-embedded tissues (ICB cohort). Methylation levels were associated with molecular and clinicopathological variables and analyzed with respect to response (irRECIST) and overall survival. CTLA-4 mRNA and mCTLA4 showed a significant inverse correlation (non-ICB cohort: Spearman's ρ = -0.416, P < 0.001). In ICB-treated melanoma patients, low mCTLA4 was further strongly correlated with response to therapy (P = 0.009, ANOVA) and overall survival (hazard ratio = 2.06 [95% CI: 1.29-3.29], P = 0.003). Our data strongly support the assumption that mCTLA4 predicts response to both anti-PD-1 and...Continue Reading

References

Nov 9, 2000·The New England Journal of Medicine·M EstellerJ G Herman
May 25, 2005·International Journal of Cancer. Journal International Du Cancer·Elisabetta ContardiMaria Pia Pistillo
Jun 20, 2008·The Journal of Investigative Dermatology·Kavita V ShahRandall T Moon
Jan 21, 2009·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Dimo DietrichGlen Kristiansen
Jan 21, 2011·Nature·M Raza ZaidiGlenn Merlino
May 1, 2012·Nature Biotechnology·Scott L CarterGad Getz
Feb 15, 2013·Gut·Timothy Robert ChurchUNKNOWN PRESEPT Clinical Study Steering Committee, Investigators and Study Team
Jun 4, 2013·The New England Journal of Medicine·Jedd D WolchokMario Sznol
Jul 23, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher J Nirschl, Charles G Drake
Aug 21, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Christopher D ScharerJeremy M Boss
Mar 22, 2014·The New England Journal of Medicine·Thomas F ImperialeBarry M Berger
Jun 7, 2014·Cancer Immunology Research·Zachary A CooperJennifer A Wargo
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
May 15, 2015·Nature·Stefani SprangerThomas F Gajewski
Jun 2, 2015·The New England Journal of Medicine·Dung T LeLuis A Diaz
Jun 20, 2015·Cell·UNKNOWN Cancer Genome Atlas Network
Aug 16, 2016·The Journal of Clinical Investigation·Adil I DaudMichael D Rosenblum
Oct 9, 2016·The New England Journal of Medicine·Alexander M M EggermontAlessandro Testori
Oct 18, 2016·The Journal of Urology·Kim E M van KesselEllen C Zwarthoff
Oct 30, 2016·Science·Debattama R SenW Nicholas Haining
Dec 13, 2016·The Journal of Molecular Diagnostics : JMD·Barbara UhlGlen Kristiansen
Feb 12, 2017·Cell·Padmanee SharmaAntoni Ribas
Jun 28, 2017·Nature Reviews. Clinical Oncology·Mizuki NishinoF Stephen Hodi
Sep 12, 2017·The New England Journal of Medicine·Jeffrey WeberUNKNOWN CheckMate 238 Collaborators
Dec 14, 2017·Nature·Ben YoungbloodRafi Ahmed
Jan 9, 2018·Nature Medicine·Carsten KriegBurkhard Becher

❮ Previous
Next ❯

Citations

Jul 30, 2019·Immunological Reviews·Breelyn A Wilky
Apr 14, 2020·Epigenetics : Official Journal of the DNA Methylation Society·Luka de VosDimo Dietrich
Jul 21, 2020·Immunotherapy·Luka de VosAlina Franzen
Jun 27, 2020·Clinical Epigenetics·Friederike HoffmannDimo Dietrich
Jun 11, 2020·International Journal of Molecular Sciences·Magdalena OlbrytWiesława Widłak
Jan 22, 2020·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Yaqiong ZhangBo Li
Aug 9, 2020·Clinical Epigenetics·Jeong Yeon KimHyunchul Jung
Apr 8, 2020·Journal of Cardiovascular Translational Research·Sherry-Ann BrownJoerg Herrmann
Mar 3, 2019·Scientific Reports·Justin ElseyJack L Arbiser
Nov 19, 2019·Critical Reviews in Oncology/hematology·Martina NapolitanoFederica Bertolini
Apr 4, 2021·Cancers·Yosuke IshitsukaManabu Fujimoto
Jun 3, 2021·International Journal of Molecular Sciences·Luisa ChocarroDavid Escors
Jun 3, 2021·International Journal of Molecular Sciences·Francesco PettiniOttavia Spiga
Aug 28, 2021·Cells·Emilio Francesco Giunta On Behalf Of Scito Youth

❮ Previous
Next ❯

Methods Mentioned

BETA
RNA-Seq
flow cytometry
deamination
PCR

Software Mentioned

TCGA
SPSS
SeqWare

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.